SC
KNSA icon

SummitTX Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

SummitTX Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48,808
Closed -$2.01M – 881
2025
Q4 		$2.01M Buy
+48,808
New +$1.96M 0.06% 310
2025
Q3 		– Sell
-30,200
Closed -$836K – 878
2025
Q2 		$836K Buy
+30,200
New +$769K 0.04% 401

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SummitTX Capital's KNSA Position: Q1 2026 in Review

SummitTX Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 48,808 shares — an estimated $2.01M sold.

SummitTX Capital first reported a position in KNSA in Q2 2025 and held it in 2 quarters. The position peaked at $2.01M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • SummitTX Capital reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SummitTX Capital sold 48,808 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $2.01M.
  • SummitTX Capital first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • SummitTX Capital's Kiniksa Pharmaceuticals position peaked at $2.01M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.